Doc, youve seen all of the data AVXL has PR'd including the latest showing Blarcamesine's impact on the Abclear 1, 2, and 3 groups and the most recent comparison with ADNI control group. If you were a voting of member of CHMP, what would be your vote given lack of traditional Phase III trial? Serious question here and please be as objective as possible ...
Market Data 
Markets 
AI
